Saturday, August, 24, 2019 06:19:32

Cognoa receives FDA breakthrough designation for its digital devices

These digital devices are the basis of Cognoa’s precision health platform. The FDA Breakthrough Device Program is envisioned to help patients in receiving timely access to advance technologies. Cognoa, Inc., the developer of AI-based personalized therapies and digital diagnostics, has reportedly announced that its first …

MeiraGTx and Janssen to develop gene therapies for IRD treatments

The latest transaction is the second significant collaboration by the two companies MeiraGTx Holdings Plc, a clinical-stage gene therapy company, has reportedly inked a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., in a bid to develop and commercialize gene therapies for the IRD (inherited retinal …